The Morning Journal (Lorain, OH)

Dow returns to record, S&P adds vaccine hope

- By Stan Choe and Damian J. Troise AP Business Writers Elaine Kurtenbach, Joe McDonald and Yuri Kageyama contribute­d.

The Dow Jones Industrial Average closed at a record high, erasing pandemic losses after vaccine wins.

NEW YORK » The Dow Jones Industrial Average rose to a record Monday for the first time in nine months, riding a swell of optimism that a vaccine may soon control the coronaviru­s and the economic destructio­n it’s caused.

Moderna said early in the morning that its COVID-19 vaccine appears to be 94.5% effective, according to preliminar­y data.

It’s the second time this month that a company unveiled such encouragin­g numbers about a vaccine, boosting hopes that the global economy can return to some semblance of normal next year.

Leading the way again were stocks of companies that would benefit most from an economy busting out of its forced hibernatio­n, such as airlines, movie theaters and banks. At the same time, pandemic-winning stocks that benefited from lockdown orders like Amazon and Zoom Video Communicat­ions lagged as they no longer looked like the only safe bets to play.

The Dow jumped 470.63 points, or 1.6%, to 29,950.44. It surpassed its prior closing record of 29,551.42, set in February before pandemic panic sent stocks plunging.

The S&P 500, which matters more to the performanc­e of most 401(k) accounts, added to its own record set on Friday. I

t rose 41.76, or 1.2%, to 3,626.91. The Nasdaq composite gained 94.84, or 0.8%, to 11,924.13. It lagged the rest of the market amid lessened interest for tech stocks.

Treasury yields, oil prices and stocks around the world also rallied on the shot of increased optimism. A vaccine is precisely what markets have been waiting for to pull the global economy out of its cavern, and analysts say it’s a game changer.

Of course, for all its euphoria, many risks remain for the market. Even if one or both vaccines are finally approved, it’s still uncertain when they could be widely distribute­d.

The pandemic is continuing to worsen, meanwhile, with rising coronaviru­s counts across the United States and Europe pushing government­s to bring back varying degrees of restrictio­ns on businesses.

“The vaccine could help people breathe a sigh of relief, but the devil is in the details,” said Gene Goldman, chief investment officer at Cetera Financial Group, referring to the need for more complete data and eventual distributi­on plans.

But investors for now are focusing on the possibilit­y of a world next year where customers are again going outside to work at offices, buying things at enclosed stores and heading on vacations.

It was just a week ago that Pfizer and BioNTech sent optimism soaring with their encouragin­g vaccine data results. Movietheat­er chain Cinemark has surged 58.3% since just before the announceme­nt. Stocks of smaller companies, whose prices tend to sway more with the strength of the economy, are up more than double their larger rivals over the same time: an 8.6% jump for the Russell 2000 index of small-cap stocks versus 3.3% for the S&P 500.

Stocks of companies that had thrived amid lockdowns and vigilance about the virus, meanwhile, have lagged. Amazon, Netflix and Etsy are all down more than 5% since just before Pfizer’s announceme­nt. Zoom has sunk 20.2%.

The shift in market sentiment is perhaps most clear in the stock prices of Peloton, with its at-home exercise bikes, and the Planet Fitness chain of gyms. Peloton is down 18.8% since Nov. 6, versus a gain of 5.7% for Planet Fitness.

Investors aren’t abandoning Big Tech amid the vaccine hopes. But the ability of Apple, Microsoft and other behemoths to stand so clearly apart from the rest of the market has diminished a bit.

That has many money managers pulling some of the big profits made on Big Tech and steering them into beaten-down areas of the market.

Newspapers in English

Newspapers from United States